|Slideshows|June 7, 2016

Psychiatry Roundup: Suicide, Overdose, and Self-Harm

A recent study reported that burnout rates in one hospital were over 75%. This story and more in our psychiatry roundup.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

“Porosity”: Connecting 2 Western Cultural Psychiatric Discourses in Tokyo by Way of Naples

ByVincenzo Di Nicola, MPhil, MD, PhD, FCAHS, DLFAPA, DFCPA, FACPsych, FRSC

October 29th 2025

Social Determinants of Health and Mental Health: Concepts and Practice of Growing Relevance

ByRenato D. Alarcón, MD, MPH,Dilip V. Jeste, MD

October 16th 2025

The Psychiatric Lens on Extraordinary Experiences: Improving Care Without Misdiagnosis

ByMarina Weiler, PhD,Marieta Pehlivanova, PhD,Philip J. Cozzolino, PhD,J. Kim Penberthy, PhD, ABPP

September 29th 2025

Social Psychiatry and Culturally Relevant Psychotherapy at the APA Annual Meeting

ByLeah Kuntz,Vincenzo Di Nicola, MPhil, MD, PhD, FCAHS, DLFAPA, DFCPA, FACPsych, FRSC

May 28th 2025

After the Wildfires: Reflections on Positive Psychiatry and Posttraumatic Growth

ByDave Baron, DO, MSEd

March 4th 2025

Latest CME

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Psychiatry Roundup: Suicide, Overdose, and Self-Harm

Newsletter

Related Content

“Porosity”: Connecting 2 Western Cultural Psychiatric Discourses in Tokyo by Way of Naples

Social Determinants of Health and Mental Health: Concepts and Practice of Growing Relevance

The Psychiatric Lens on Extraordinary Experiences: Improving Care Without Misdiagnosis

Social Psychiatry and Culturally Relevant Psychotherapy at the APA Annual Meeting

After the Wildfires: Reflections on Positive Psychiatry and Posttraumatic Growth

Latest CME

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Psychedelic PSX-001 for Generalized Anxiety Disorder: A Conversation With Lou Barbato, MD

Antidotes to Fear of Death

Psychiatry Wrapped 2025: Year in Review

Catatonia Crisis: Navigating the IV Lorazepam Shortage

The Future Directions of Psychedelics: A Conversation With Guy Goodwin, MD